SLC6A3 and Parkinson disease: Both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved striatal dopamine transporter (DAT) imaging as a tool for differentiating PD from ET (EMA 2007; FDA 2011), but DAT imaging involves radiation, is expensive and has limited availability.